Objective: Overweight/obesity is associated with relative growth hormone (GH) deficiency and increased fracture risk. We hypothesized that GH administration would improve bone endpoints in individuals with overweight/obesity. Design: An 18-month, randomized, double-blind, placebo-controlled study of GH, followed by 6-month observation. Methods: In this study, 77 adults (53% men), aged 18-65 years, BMI ≥ 25 kg/m2, and BMD T- or Z-score ≤ -1.0 were randomized to daily subcutaneous GH or placebo, targeting IGF1 in the upper quartile of the age-appropriate normal range. Forty-nine completed 18 months. DXA, volumetric quantitative CT, and high-resolution peripheral quantitative CT were performed. Results: Pre-treatment mean age (48 ± 12 years), BMI (33.1 ± 5.7 kg/m2), and BMD were similar between groups. P1NP, osteocalcin, and CTX increased (P < 0.005) and visceral adipose tissue decreased (P = 0.04) at 18 months in the GH vs placebo group. Hip and radius aBMD, spine and tibial vBMD, tibial cortical thickness, and radial and tibial failure load decreased in the GH vs placebo group (P < 0.05). Between 18 and 24 months (post-treatment observation period), radius aBMD and tibia cortical thickness increased in the GH vs placebo group. At 24 months, there were no differences between the GH and placebo groups in bone density, structure, or strength compared to baseline. Conclusions: GH administration for 18 months increased bone turnover in adults with overweight/obesity. It also decreased some measures of BMD, bone microarchitecture, and bone strength, which all returned to pre-treatment levels 6 months post-therapy. Whether GH administration increases BMD with longer treatment duration, or after mineralization of an expanded remodeling space post-treatment, requires further investigation.
Objective: Overweight/obesity is associated with relative growth hormone (GH) deficiency and increased fracture risk. We hypothesized that GH administration would improve bone endpoints in individuals with overweight/obesity. Design: An 18-month, randomized, double-blind, placebo-controlled study of GH, followed by 6-month observation. Methods: In this study, 77 adults (53% men), aged 18-65 years, BMI ≥ 25 kg/m2, and BMD T- or Z-score ≤ -1.0 were randomized to daily subcutaneous GH or placebo, targeting IGF1 in the upper quartile of the age-appropriate normal range. Forty-nine completed 18 months. DXA, volumetric quantitative CT, and high-resolution peripheral quantitative CT were performed. Results: Pre-treatment mean age (48 ± 12 years), BMI (33.1 ± 5.7 kg/m2), and BMD were similar between groups. P1NP, osteocalcin, and CTX increased (P < 0.005) and visceral adipose tissue decreased (P = 0.04) at 18 months in the GH vs placebo group. Hip and radius aBMD, spine and tibial vBMD, tibial cortical thickness, and radial and tibial failure load decreased in the GH vs placebo group (P < 0.05). Between 18 and 24 months (post-treatment observation period), radius aBMD and tibia cortical thickness increased in the GH vs placebo group. At 24 months, there were no differences between the GH and placebo groups in bone density, structure, or strength compared to baseline. Conclusions: GH administration for 18 months increased bone turnover in adults with overweight/obesity. It also decreased some measures of BMD, bone microarchitecture, and bone strength, which all returned to pre-treatment levels 6 months post-therapy. Whether GH administration increases BMD with longer treatment duration, or after mineralization of an expanded remodeling space post-treatment, requires further investigation.
Authors: Michael Bligh; Luc Bidaut; R Allen White; William A Murphy; Donna M Stevens; Dianna D Cody Journal: Acad Radiol Date: 2009-02 Impact factor: 3.173
Authors: Miriam A Bredella; Anu V Gerweck; Eleanor Lin; Melissa G Landa; Martin Torriani; David A Schoenfeld; Linda C Hemphill; Karen K Miller Journal: J Clin Endocrinol Metab Date: 2013-07-03 Impact factor: 5.958
Authors: Gherardo Mazziotti; Antonio Bianchi; Stefania Bonadonna; Monica Nuzzo; Vincenzo Cimino; Alessandra Fusco; Laura De Marinis; Andrea Giustina Journal: J Bone Miner Res Date: 2006-04-05 Impact factor: 6.741
Authors: Helena Johansson; John A Kanis; Anders Odén; Eugene McCloskey; Roland D Chapurlat; Claus Christiansen; Steve R Cummings; Adolfo Diez-Perez; John A Eisman; Saeko Fujiwara; Claus-C Glüer; David Goltzman; Didier Hans; Kay-Tee Khaw; Marc-Antoine Krieg; Heikki Kröger; Andrea Z LaCroix; Edith Lau; William D Leslie; Dan Mellström; L Joseph Melton; Terence W O'Neill; Julie A Pasco; Jerilynn C Prior; David M Reid; Fernando Rivadeneira; Tjerd van Staa; Noriko Yoshimura; M Carola Zillikens Journal: J Bone Miner Res Date: 2014-01 Impact factor: 6.741
Authors: A C Looker; H W Wahner; W L Dunn; M S Calvo; T B Harris; S P Heyse; C C Johnston; R Lindsay Journal: Osteoporos Int Date: 1998 Impact factor: 4.507
Authors: B C C Khoo; K Brown; C Cann; K Zhu; S Henzell; V Low; S Gustafsson; R I Price; R L Prince Journal: Osteoporos Int Date: 2008-12-24 Impact factor: 4.507
Authors: Laura E Dichtel; Kevin C J Yuen; Miriam A Bredella; Anu V Gerweck; Brian M Russell; Ariana D Riccio; Michelle H Gurel; Patrick M Sluss; Beverly M K Biller; Karen K Miller Journal: J Clin Endocrinol Metab Date: 2014-12 Impact factor: 5.958
Authors: Karen K Miller; Miriam A Bredella; Melanie S Haines; Laura E Dichtel; Kate Santoso; Martin Torriani Journal: Int J Obes (Lond) Date: 2020-05-13 Impact factor: 5.095